Implementation of an integrated infectious disease and substance use disorder team for injection drug use-associated infections: a qualitative study
Background Hospitalizations for severe injection drug use-related infections (SIRIs) are characterized by high costs, frequent patient-directed discharge, and high readmission rates. Beyond the health system impacts, these admissions can be traumatizing to people who inject drugs (PWID), who often receive inadequate treatment for their substance use disorders (SUD). The Jackson SIRI team was developed as an integrated infectious disease/SUD treatment intervention for patients hospitalized at a public safety-net hospital in Miami, Florida in 2020. We conducted a qualitative study to identify patient- and clinician-level perceived implementation barriers and facilitators to the SIRI team intervention. Methods Participants were patients with history of SIRIs (n = 7) and healthcare clinicians (n = 8) at one implementing hospital (Jackson Memorial Hospital). Semi-structured qualitative interviews were performed with a guide created using the Consolidated Framework for Implementation Research (CFIR). Interviews were transcribed, double coded, and categorized by study team members using CFIR constructs. Results Implementation barriers to the SIRI team intervention identified by participants included: (1) complexity of the SIRI team intervention; (2) lack of resources for PWID experiencing homelessness, financial insecurity, and uninsured status; (3) clinician-level stigma and lack of knowledge around addiction and medications for opioid use disorder (OUD); and (4) concerns about underinvestment in the intervention. Implementation facilitators of the intervention included: (1) a non-judgmental, harm reduction-oriented approach; (2) the team’s advocacy for PWID as a means of institutional culture change; (3) provision of close post-hospital follow-up that is often inaccessible for PWID; (4) strong communication with patients and their hospital physicians; and (5) addressing diverse needs such as housing, insurance, and psychological wellbeing. Conclusion Integration of infectious disease and SUD treatment is a promising approach to managing patients with SIRIs. Implementation success depends on institutional buy-in, holistic care beyond the medical domain, and an ethos rooted in harm reduction across multilevel (inner and outer) implementation contexts..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Addiction science & clinical practice - 18(2023), 1 vom: 07. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hervera, Belén [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Endocarditis |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s13722-023-00363-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR05142567X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR05142567X | ||
| 003 | DE-627 | ||
| 005 | 20230510062242.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230508s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13722-023-00363-4 |2 doi | |
| 035 | |a (DE-627)SPR05142567X | ||
| 035 | |a (SPR)s13722-023-00363-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hervera, Belén |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Implementation of an integrated infectious disease and substance use disorder team for injection drug use-associated infections: a qualitative study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background Hospitalizations for severe injection drug use-related infections (SIRIs) are characterized by high costs, frequent patient-directed discharge, and high readmission rates. Beyond the health system impacts, these admissions can be traumatizing to people who inject drugs (PWID), who often receive inadequate treatment for their substance use disorders (SUD). The Jackson SIRI team was developed as an integrated infectious disease/SUD treatment intervention for patients hospitalized at a public safety-net hospital in Miami, Florida in 2020. We conducted a qualitative study to identify patient- and clinician-level perceived implementation barriers and facilitators to the SIRI team intervention. Methods Participants were patients with history of SIRIs (n = 7) and healthcare clinicians (n = 8) at one implementing hospital (Jackson Memorial Hospital). Semi-structured qualitative interviews were performed with a guide created using the Consolidated Framework for Implementation Research (CFIR). Interviews were transcribed, double coded, and categorized by study team members using CFIR constructs. Results Implementation barriers to the SIRI team intervention identified by participants included: (1) complexity of the SIRI team intervention; (2) lack of resources for PWID experiencing homelessness, financial insecurity, and uninsured status; (3) clinician-level stigma and lack of knowledge around addiction and medications for opioid use disorder (OUD); and (4) concerns about underinvestment in the intervention. Implementation facilitators of the intervention included: (1) a non-judgmental, harm reduction-oriented approach; (2) the team’s advocacy for PWID as a means of institutional culture change; (3) provision of close post-hospital follow-up that is often inaccessible for PWID; (4) strong communication with patients and their hospital physicians; and (5) addressing diverse needs such as housing, insurance, and psychological wellbeing. Conclusion Integration of infectious disease and SUD treatment is a promising approach to managing patients with SIRIs. Implementation success depends on institutional buy-in, holistic care beyond the medical domain, and an ethos rooted in harm reduction across multilevel (inner and outer) implementation contexts. | ||
| 650 | 4 | |a Opioid use disorder |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Injection drug use |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Infectious diseases |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Harm reduction |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Endocarditis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Implementation science |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Seo, Grace |4 aut | |
| 700 | 1 | |a Bartholomew, Tyler S. |4 aut | |
| 700 | 1 | |a Chueng, Teresa A. |4 aut | |
| 700 | 1 | |a Suarez, Edward |4 aut | |
| 700 | 1 | |a Forrest, David W. |4 aut | |
| 700 | 1 | |a Hernandez, Salma |4 aut | |
| 700 | 1 | |a Rodriguez, Allan E. |4 aut | |
| 700 | 1 | |a Tookes, Hansel E. |4 aut | |
| 700 | 1 | |a Doblecki-Lewis, Susanne |4 aut | |
| 700 | 1 | |a Serota, David P. |0 (orcid)0000-0001-8505-6617 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Addiction science & clinical practice |d London : BioMed Central, 2007 |g 18(2023), 1 vom: 07. Feb. |w (DE-627)SPR032188838 |w (DE-600)2492632-2 |x 1940-0640 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:1 |g day:07 |g month:02 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13722-023-00363-4 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 1 |b 07 |c 02 | ||